IGHE and cancer: In this context, a phase I dose escalation trial (NCT02546921) demonstrated the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumors expressing folate receptor-alpha, thus supporting the potential of IgE therapy for cancer [315].